07 August 2017
Visiongain has launched a new pharma report Biologics Market Report : Evaluation of Therapeutic Segments Including Monoclonal Antibodies, Insulin, Fusion Proteins, Interferons and Gene Therapies; Prediction of Leading National Markets (US, Japan, EU5 and BRIC); Investigation of Top Products Including Humira, Remicade, Lantus and Enbrel; and Assessment of R&D Including Sirukumab and NurOwn
Biologics (biological drugs) are products derived from living organisms (from sources such as microorganisms, animals and human beings) - including agents obtained directly from living organisms, and products created by recombinant genetic engineering technology. Biologics include a wide range of medicines, including therapeutic proteins, monoclonal antibodies (mAbs) and gene therapies.
Biopharmaceuticals form a vital part of the treatment portfolio for many serious chronic disorders, including cancer, diabetes, hepatitis and autoimmune diseases. This highly lucrative market is set to experience high sales between 2017 and 2027, but will have to adapt to many new challenges along the way.
The lead Visiongain report analyst for this report commented; “Biologics are crucial for the treatment of many serious chronic disorders such as cancer, diabetes, hepatitis and autoimmune diseases. These effective but highly complex therapies come at a price, with some treatments costing more than $75,000 a year. They are able to generate multi-billion dollar revenues, with biologics representing seven out of the top ten best-selling drugs in 2016.
The emergence of biosimilars is set to disrupt this market - although they can be a positive or a negative influence, depending on how companies adapt to their presence. Patents on many leading biologics are due to expire during the forecast period of this report, and payers are eager to cut costs in the face of declining healthcare budgets. As such, this is a crucial period in the history of the global biologics market, one which will determine its long-term future.”
The Global market is highly competitive with many different players entering the market. The report discusses products from leading companies in the market. Notable companies in the Global Biologics market include Abbvie, Amgen, Pfizer, Roche, Biogen, Johnson & Johnson, Merck & Co. and Sanofi amongst others.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
14 July 2021
Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.